• Tue. Sep 20th, 2022

Ventripoint Successfully Completes European Commission QMS Certification Surveillance Audit

ByChad J. Johnson

May 14, 2022

Toronto, Ontario – The Newswire – January 24, 2022 – Ventripoint Diagnostics Ltd (“ventripoint“or the”Company“), (TSX V: VPT) (OTC: VPTDF) is pleased to announce that it has successfully completed a surveillance audit of its quality assurance system in accordance with the Medical Device Directive 93/42/EEC (MDD), Annex II, with no results. . This is the first surveillance audit since Ventripoint’s last full recertification (see NR of March 9, 2021).

The audit carried out by an EU-based Notified Body has confirmed that Ventripoint remains compliant with the requirements of the EU Medical Device Directive. Our continued certification allows us to continue to market in CE marked European countries, which include the European Economic Area, Switzerland and, until 2023, the United Kingdom and until Ventripoint changes to the new European regulation on medical devices (MDR).

“This significant achievement for the organization demonstrates the commitment of the entire Ventripoint team to designing, developing, manufacturing and distributing high quality products and improving the lives of patients,” said the Dr. George Adams, CEO of Ventripoint.

About Ventripoint Diagnostics Ltd.

ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable and reference alternative allows cardiologists to have greater confidence in the care of their patients. Providing better patient care serves as the springboard and baseline standard for all Ventripoint products that guide our future developments. Additionally, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by market regulatory approvals in the US, Europe and Canada.

For more information, please contact:

Dr. George Adams

[email protected]

519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Before Looking for statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “target”, “ongoing”, “may”, “will”, “plan”, ” should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. Forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on forward-looking statements and information as the Company cannot guarantee that they will prove to be accurate.

Because forward-looking statements and information relate to future events and conditions, they, by their very nature, involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the Company’s most recent annual MD&A risk factors available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the above list of factors is not exhaustive. The forward-looking statements included in this press release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this press release are made as of the date hereof, and the Company undertakes no obligation to publicly update or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise. , except as required by applicable securities laws.